Home › Metastatic Cancer › Pennsylvania
Metastatic Cancer clinical trials in Pennsylvania
65 studies for Metastatic Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07335497Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Nov 12, 2026 · NCT05372640Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04585958A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC Altoona, Altoona
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- and 18 more
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Univ of Pennsylvania, Abramson Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Abramson Cancer Center, Philadelphia
- AHN Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06216301Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Thomas Jefferson University, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07562152A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Nov 6, 2026 · NCT05384626A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- St. Luke's University Health Network, Bethlehem
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
- University of Pennsylvania Hospital, Philadelphia
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Pennsylvania Hospital, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213804VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Cancer Care Associates of York (site 206), York
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Nov 4, 2026 · NCT03556228A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Alliance Cancer Specialists, PC, Horsham
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute, Lancaster
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University, Philadelphia
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05614739A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- Thomas Jefferson University Hospital, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Nov 3, 2026 · NCT04802759Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric Patients
- Children's Hospital of Philadelphia, Phildelphia
RecruitingEarly phase 1
Ages 12 to 17 · All sexes · Updated Nov 2, 2026 · NCT07658768Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06943755Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05803382Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
- University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06127407A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Asplundh Cancer Pavilion, Willow Grove
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06769698A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT04657068A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06244771AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Philadelphia
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Oct 16, 2026 · NCT07038343Window of Opportunity in Preserving Laryngeal Function Trial
- UPMC Hillman Cancer, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07423078Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06757634A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06863272A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
- AHN Allegheny General Hospital, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT07218380FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT05919264Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06697301The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
- Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07213817A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Fox Chase Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 24, 2026 · NCT05118789SLV-154 Treatment of Advanced Cancers
- Fox Chase Cancer Center, Philadelphia
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT06771219Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- Lankenau Medical Center, Paoli
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07028489From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.